Drug resistance mutation profile and accumulation kinetics in human immunodeficiency virus-positive individuals infected with subtypes B and F failing highly active antiretroviral therapy are influenced by different viral codon usage patterns

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 12, 2008, Pages 4497-4502

  Waleria Aleixo A ^a   Martins, A N ^b   Arruda, M B ^b   Brindeiro, R M ^b   Da Silva, R M ^b   Nobre, F F ^b   Greco, D B ^a   Tanuri, A ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; BRAZIL; CODON USAGE; FEMALE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SUBSTITUTION LINE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; CD4 LYMPHOCYTE COUNT; CODON; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MUTATION; RNA, VIRAL; TREATMENT FAILURE;

EID: 57049105350     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00820-08     Document Type: Article

References (37)

1. Abecasis, A. B., K. Deforche, J. Snoeck, L. T. Bacheler, P. McKenna, A. P. Carvalho, P. Gomes, R. J. Camacho, and A. M. Vandamme. 2005. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 19:1799-1806.
2. Apetrei, C., D. Descamps, G. Collin, I. Loussert-Ajaka, F. Damond, M. Duca, F. Simon, and F. Brun-Vézinet. 1998. Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility. J. Virol. 72:3534-3538.
3. Barreto, C. C., A. Nishyia, L. V. Araújo, J. E. Ferreira, M. P. Busch, and E. C. Sabino. 2006. Trends in antiretroviral drug resistance and clade distributions among HIV-1-infected blood donors in Sao Paulo, Brazil. J. Acquir. Immune Defic. Syndr. 41:338-341.
4. Brennan, C. A., C. Brites, P. Bodelle, A. Golden, J. Hackett, Jr., V. Holzmayer, P. Swanson, A. Vallari, J. Yamaguchi, S. Devare, C. Pedroso, A. Ramos, and R. Badaro.. 2007. HIV-1 strains identified in Brazilian blood donors: significant prevalence of B/F1 recombinants. AIDS Res. Hum. Retroviruses 23:1434-1441.
5. Brindeiro, R. M., R. S. Diaz, E. C. Sabino, M. G. Morgado, I. L. Pires, L. Brigido, M. C. Dantas, D. Barreira, P. R. Teixeira, and A. Tanuri for the Brazilian network for drug resistance surveillance.. 2003. Brazilian network for HIV drug resistance surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS 17:1063-1069.
6. Cane, P. A., A. de Ruiter, P. Rice, R. Wiselka, R. Fox, and D. Pillay. 2001. Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom. J. Clin. Microbiol. 39:2652-2654.
7. Carrion, G., L. Eyzaguirre, S. M. Montano, V. Laguna-Torres, M. Serra, N. Aguayo, M. M. Avila, D. Ruchansky, M. A. Pando, J. Vinoles, J. Perez, A. Barboza, G. Chauca, A. Romero, A. Galeano, P. J. Blair, M. Weissenbacher, D. L. Birx, J. L. Sanchez, J. G. Olson, and J. K. Carr. 2004. Documentation of subtype C HIV type 1 strains in Argentina, Paraguay, and Uruguay. AIDS Res. Hum. Retroviruses 20:1022-1025.
8. Coakley, E. P., J. M. Gillis, and S. M. Hammer. 2000. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 14:F9-F15.
9. de Oliveira, T., K. Deforche, S. Cassol, M. Salminen, D. Paraskevis, C. Seebregts, J. Snoeck, E. J. van Rensburg, A. M. J. Wensing, D. A. van de Vijver, C. A. Boucher, R. Camacho, and A.-M. Vandamme.. 2005. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21:3797-3800.
10. De Sá Filho, D. J., M. C. Sucupira, M. M. Caseiro, E. C. Sabino, R. S. Diaz, and L. M. Janini. 2006. Identification of two HIV type 1 circulating recombinant forms in Brazil. AIDS Res. Hum. Retroviruses 22:1-13.
11. Deval, J., B. Selmi, J. Boretto, M. P. Egloff, C. Guerreiro, S. Sarfati, and B. Canard. 2002. The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogues. J. Biol. Chem. 277:42097-42104.
12. Dilernia, D. A., A. M. Gomez, L. Lourtau, R. Marone, M. H. Losso, H. Salomón, and M. Gómez-Carrillo. 2007. HIV type 1 genetic diversity surveillance among newly diagnosed individuals from 2003 to 2005 in Buenos Aires, Argentina. AIDS Res. Hum. Retroviruses 23:1201-1207.
13. Doualla-Bell, F., A. Avalos, B. Brenner, T. Gaolathe, M. Mine, S. Gaseitsiwe, M. Oliveira, D. Moisi, N. Ndwapi, H. Moffat, M. Essex, and M. A. Wainberg. 2006. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob. Agents Chemother. 50:4182-4185.
14. Dumans, A. T., M. A. Soares, E. S. Machado, S. Hué, R. M. Brindeiro, D. Pillay, and A. Tanuri. 2004. Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus Type 1 subtypes may influence mutational routes to drug resistance. J. Infect. Dis. 189:1232-1238.
15. Gonzalez, L. M., R. M. Brindeiro, R. S. Aguiar, H. S. Pereira, C. M. Abreu, M. A. Soares, and A. Tanuri. 2004. Impact of nelfinavir resistance mutations on in vitro phenotype, fitness and replication capacity of human immunodeficiency virus type with B and C proteases. Antimicrob. Agents Chemother. 48:3552-3555.
16. Gonzalez, L. M. F., R. M. Brindeiro, M. Tarin, A. Calazans, M. A. Soares, S. Cassol, and A. Tanuri. 2003. The subtype C of human immunodeficiency virus type 1 protease presents an in vitro hypersusceptibility to protease inhibitor Lopinavir. Antimicrob. Agents Chemother. 47:2817-2822.
17. Grossman, Z., V. Istomin, D. Averbuch, M. Lorber, K. Risenberg, I. Levi, M. Chowers, M. Burke, N. Bar-Yaacov, J. M. Schapiro, and Israel AIDS Multi-Center Study Group.. 2004. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS 18:909-915.
18. Hemelaar, J., E. Gouws, P. D. Ghys, and S. Osmanov. 2006. Global and regional distribution of HIV-1 genetics subtypes and recombinants in 2004. AIDS 20:W13-W23.
19. Hierholzer, J., S. Montano, M. Hoelscher, M. Negrete, M. Hierholzer, M. M. Avila, M. G. Carrillo, J. C. Russi, J. Vinoles, A. Alava, M. E. Acosta, A. Gianella, R. Andrade, J. L. Sanchez, G. Carrion, J. L. Sanchez, K. Russell, M. Robb, D. Birx, F. McCutchan, and J. K. Carr. 2002. Molecular epidemiology of HIV type 1 in Ecuador, Peru, Bolivia, Uruguay, and Argentina. AIDS Res. Hum. Retroviruses 18:1339-1350.
20. Iversen, A. K. N., R. W. Shafer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro, and T. C. Merigan.. 1996. Multidrug-resistant HIV-1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
21. Jeeninga, R. E., M. Hoogenkamp, M. Armand-Ugon, M. de Baar, K. Verhoef, and B. Berkhout. 2000. Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. J. Virol. 74:3740-3751.
22. Johnson, V. A., F. Brun-Vezinet, B. Clotet, H. F. Gunthard, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. 2008. Update of the drug resistance mutations in HIV-1: spring 2008. Top. HIV Med. 16:62-68.
23. Kumar, S., K. Tamura, and M. Nei.. 2004. MEGA 3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief. Bioinformatics 5:150-163.
24. Loemba, H., B. Brenner, M. A. Parniak, S. Ma'ayan, B. Spira, D. Moisi, M. Oliveira, M. Detorio, and M. A. Wainberg. 2002. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob. Agents Chemother. 46:2087-2094.
25. Miller, M. D., N. A. Margot, K. Hertogs, B. Larder, and V. Miller. 2001. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids 20:1025-1028.
26. Miller, V., and B. Larder. 2001. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir. Ther. 6:25-44.
27. Poveda, E., de-Mendoza, C., N. Parkin, S. Choe, P. García-Gasco, A. Corral, and V. Soriano. 2008. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. AIDS 22:611-616.
28. Renjifo, B., P. Gilbert, B. Chaplin, G. Msamanga, D. Mwakagile, G. Msamanga, W. Fawzi, and M. Essex. 2004. Preferential in-utero transmission of HIV-1 subtype C compared to HIV-1 subtype A or D. AIDS 18:1629-1636.
29. Ríos, M., E. Delgado, L. Pérez-Alvarez, J. Fernández, P. Gálvez, E. V. de Parga, V. Yung, M. M. Thomson, and R. Nájera. 2007. Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile. J. Med. Virol. 79:647-656.
30. Sá Ferreira, J. A., P. A. Brindeiro, S. Chequer-Fernandez, A. Tanuri, and M. G. Morgado. 2007. Human immunodeficiency virus-1 subtypes and antiretroviral drug resistance profiles among drug-naïve Brazilian blood donors. Transfusion 47:97-102.
31. Shafer, R. W., M. J. Kozal, M. A. Winters, A. K. Iversen, D. A. Katzenstein, M. V. Ragni, W. A. Meyer, 3rd, P. Gupta, S. Rasheed, R. Coombs, M. Katzman, S. Fiscus, and T. C. Merigan.. 1994. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 169:722-729.
32. Shirasaka, T., M. F. Kavlick, T. Ueno, W. Y. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya.. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
33. Soares, E. A., A. F. Santos, T. M. Sousa, E. Sprinz, A. M. Martinez, J. Silveira, A. Tanuri, and M. A. Soares. 2007. Differential drug resistance acquisition in HIV-1 of subtypes B and C. PLoS ONE 2:e730.
34. Taylor, B. S., M. E. Sobieszczyk, F. E. McCutchan, and S. M. Hammer. 2008. The challenge of HIV-1 subtype diversity. N. Engl. J. Med. 358:1590-1602.
35. Teixeira, P. R., M. A. Vitoria, and J. Barcarolo. 2004. Antiretroviral treatment in resource-poor settings: the Brazilian experience. AIDS 18(Suppl. 3):S5-S7.
36. Triques, K., A. Bourgeois, N. Vidal, E. Mpoudi-Ngole, C. Mulanga-Kabeya, N. Nzilambi, N. Torimiro, E. Saman, E. Delaporte, and M. Peeters. 2000. Near-full-length genome sequencing of divergent African HIV type 1 subtype F viruses leads to the identification of a new HIV type 1 subtype designated K. AIDS Res. Hum. Retroviruses 16:139-151.
37. Yahi, N., C. Tamalet, C. Tourres, N. Tivoli, and J. Fantini. 2007. Mutation L210W of HIV-1 reverse transcriptase in patients receiving combination therapy. Incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase. J. Biomed. Sci. 7:507-513.